Evidence map›Paper›PMID 30209750›Full record

ArticleAdvances in therapy2018

Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.

Sunnie Kim, James E Signorovitch, Hongbo Yang, Oscar Patterson-Lomba, Cheryl Q Xiang, Brian Ung, Monika Parisi, John L Marshall

4 registry-linked trialsOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 50 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 3 pooled it
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02027428 phase3completednot on this map

A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

TypeinterventionalSponsorCelgeneRan2014 to 2019Enrolled427ConditionsSquamous Cell Carcinoma, Non-Small-Cell LungArmsAbraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance), Best Supportive Care (Maintenance)
NCT02250326 phase2completednot on this map

A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Immunotherapy of Durvalumab (MEDI4736), Or As Monotherapy In Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC): Abound.2L+

TypeinterventionalSponsorCelgeneRan2015 to 2023Enrolled240ConditionsCarcinoma, Non-Small-Cell LungArmsnab-paclitaxel IV, CC-486, Duravalumab
NCT02555813 completednot on this map

Multicenter Non-interventional Study to Investigate Safety, Tolerability and Efficacy of Nab-paclitaxel in Clinical Routine Treatment of First-line Pancreatic Cancer Patients

TypeobservationalSponsorCelgeneRan2015 to 2020Enrolled317ConditionsMetastatic Pancreatic CancerArmsAbraxane, Gemcitabine
NCT02670746 terminatednot on this map

Non-interventional Observational Post-authorization Study to Assess Clinical and Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Routine Clinical Practice Treating Pancreatic Cancer (TRUST)

TypeobservationalSponsorCelgeneRan2015 to 2017Enrolled44ConditionsPancreatic Neoplasms
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sunnie KimMedStar Georgetown University Hospital, Washington, DC, USA. Sunnie.Kim@gunet.georgetown.edu.
James E SignorovitchAnalysis Group, Inc., Boston, MA, USA.
Hongbo YangAnalysis Group, Inc., Boston, MA, USA.
Oscar Patterson-LombaAnalysis Group, Inc., Boston, MA, USA.
Cheryl Q XiangAnalysis Group, Inc., Boston, MA, USA.
Brian UngCelgene Corporation, Summit, NJ, USA.
Monika ParisiCelgene Corporation, Summit, NJ, USA.
John L MarshallRuesch Center for the Cure of GI Cancers, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Analysis Group (United States) · USGeorgetown University Medical Center · USMedStar Georgetown University Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionnab-Paclitaxel plus gemcitabine (nab-P + G) and FOLFIRINOX (FFX) are among the most common first-line (1L) therapies for metastatic adenocarcinoma of the pancreas (MPAC), but real-world data on their comparative effectiveness are limited.

methodsThis retrospective cohort study compared the efficacy and safety of 1L nab-P + G versus FFX, overall and under specific treatment sequences. Medical records were reviewed by 215 US physicians who provided information on MPAC patients who initiated 1L therapy with nab-P + G or FFX between April 1, 2015 and December 31, 2015. Study outcomes were overall survival (OS) and tolerability. OS was compared using Kaplan-Meier curves and adjusted Cox proportional hazards models.

resultsIn total, 654 medical records were reviewed, including those of 337 and 317 patients initiated on nab-P + G and FFX as 1L MPAC therapy, respectively. nab-P + G-initiated patients were older, less likely to have ECOG ≤ 1, and had more comorbidities than FFX-initiated patients. Median OS (mOS) was 12.1 and 13.8 months for nab-P + G- and FFX-initiated patients, respectively (HR = 0.99, P = 0.96). Among patients with ECOG ≤ 1, mOS was 14.1 and 13.7 months, respectively (HR = 1.00, P = 0.99). Among patients with 1L nab-P + G and FFX, 36.1% and 41.3% received 2L therapy and experienced mOS of 16.3 and 16.6 months, respectively (HR = 1.04, P = 0.76). The rates of diarrhea, fatigue, mucositis, and nausea and vomiting were significantly higher in the FFX than nab-P + G cohort.

conclusionThe real-world survival was similar between patients receiving 1L nab-P + G or FFX both overall and among patients who received active 2L treatments. In addition, nab-P + G was associated with significantly lower rates of common AEs compared with FFX.

fundingCelgene.

Indexed as

AdenocarcinomaAlbuminsAntineoplastic Combined Chemotherapy ProtocolsPaclitaxelPancreatic NeoplasmsAgedAntineoplastic AgentsCohort StudiesDeoxycytidineFemaleFluorouracilGemcitabineHumansIrinotecanLeucovorinMale130-nm albumin-bound paclitaxelAlbuminsAntineoplastic AgentsDeoxycytidineFluorouracilfolfirinoxGemcitabineIrinotecanLeucovorinOxaliplatinPaclitaxelAdverse eventsFOLFIRINOXMetastatic adenocarcinoma of the pancreasnab-PaclitaxelReal-world evidenceSurvival analysis

Identifiers

PMID30209750
PMCPMC6182639
OpenAlexW2890376061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.